Collectively, these results suggest that silencing of LRP5 suppresses the stemness of CRC by inhibiting the canonical Wnt/β‐catenin and IL‐6/STA3 pathways simultaneously, and targeting the overexpressed LRP5 could be a valuable strategy for CRC treatment. This evidence concerns the gene LRP5 and colorectal carcinoma.